X
[{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Health Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dalton Expands Cannabinoids Capabilities","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Dalton Pharma Services"},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Hong Kong Teson Pharma","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"$3.0 million","newsHeadline":"Correvio Partners with Hong Kong Teson Pharma Limited","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Correvio Pharma"},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"$76.0 million","newsHeadline":"Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Correvio Pharma"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valeo Pharma\u2019s Redesca\u2122 Receives Positive Recommendation for Public Reimbursement in Quebec","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Biosimilar","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Valeo Pharma"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Group Purchasing Organizations","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Valeo Pharma"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Desjardins Capital Markets","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement From Investissement Quebec","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Valeo Pharma"},{"orgOrder":0,"company":"Teligent, Inc","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"$45.8 million","upfrontCash":"Undisclosed","newsHeadline":"Hikma Expands Into Canada with Acquisition of Teligent Sterile Injectable Assets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Teligent, Inc"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmascience Introduces Myinfla(TM) (Colchicine 0.5 Mg Extended-Release Tablets), a New Repurposed Treatment Now Available in Canada to Reduce the Risk of Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharmascience Inc."}]
Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in CANADA
Filters
Details:
The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.
Lead Product(s):
Atropine
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Atropine-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Hikma Pharmaceuticals
Deal Size: $45.8 million
Upfront Cash: Undisclosed
Deal Type: Acquisition
January 17, 2022
Details:
The net proceeds of the Offering and Concurrent Private Placement will be used to support commercial efforts related to the recently launched products (Redesca™, Enerzair®, and Atectura®).
Lead Product(s):
Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Redesca
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Desjardins Capital Markets
Deal Size: $10.0 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
November 24, 2021
Details:
Under the terms of the contracts, the GPOs have listed Redesca™ and Redesca HP™, Valeo’s leading low molecular weight heparin (“LMWH”) biosimilar, as well as three other hospital products (Amikacin, Ethacrynate Sodium and Benztropine), for a 3-year period.
Lead Product(s):
Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Redesca
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Group Purchasing Organizations
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
October 13, 2021
Details:
Myinfla (colchicine 0.5 mg extended-release tablets) inhibits the Beta tubulin polymerisation, which is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease.
Lead Product(s):
Colchicine
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Myinfla
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 22, 2021
Details:
Redesca™ is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.
Lead Product(s):
Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Redesca
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 25, 2021
Details:
Advanz Pharma believes that Correvio's niche portfolio, consisting of an established brand, and two growing, patent-protected brands, plus a pipeline of potential product launches, are highly complementary to its current priorities and future focus.
Lead Product(s):
Vernakalant Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Advanz Pharma
Deal Size: $76.0 million
Upfront Cash: $76.0 million
Deal Type: Acquisition
May 27, 2020
Details:
The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Lead Product(s):
Tirofiban
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Hong Kong Teson Pharma
Deal Size: $3.5 million
Upfront Cash: $3.0 million
Deal Type: Agreement
March 10, 2020
Details:
Dalton receives the license amendment from Health Canada under Cannabis regulations enabling transfer of finished cGMP cannabis products to licensed dealers.
Lead Product(s):
Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Health Canada
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
January 15, 2020